Combining epigenetic and immunotherapy to combat cancer
Cancer research, 2016•AACR
The most exciting recent advance for achieving durable management of advanced human
cancers is immunotherapy, especially the concept of immune checkpoint blockade.
However, with the exception of melanoma, most patients do not respond to immunotherapy
alone. A growing body of work has shown that epigenetic drugs, specifically DNA
methyltransferase inhibitors, can upregulate immune signaling in epithelial cancer cells
through demethylation of endogenous retroviruses and cancer testis antigens. These …
cancers is immunotherapy, especially the concept of immune checkpoint blockade.
However, with the exception of melanoma, most patients do not respond to immunotherapy
alone. A growing body of work has shown that epigenetic drugs, specifically DNA
methyltransferase inhibitors, can upregulate immune signaling in epithelial cancer cells
through demethylation of endogenous retroviruses and cancer testis antigens. These …
Abstract
The most exciting recent advance for achieving durable management of advanced human cancers is immunotherapy, especially the concept of immune checkpoint blockade. However, with the exception of melanoma, most patients do not respond to immunotherapy alone. A growing body of work has shown that epigenetic drugs, specifically DNA methyltransferase inhibitors, can upregulate immune signaling in epithelial cancer cells through demethylation of endogenous retroviruses and cancer testis antigens. These demethylating agents may induce T-cell attraction and enhance immune checkpoint inhibitor efficacy in mouse models. Current clinical trials are testing this combination therapy as a potent new cancer management strategy. Cancer Res; 76(7); 1683–9. ©2016 AACR.
AACR
